Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Most patients with chronic rhinosinusitis with nasal polyps no longer used oral corticosteroids after using dupilumab, according to data presented at the American College of Allergy, Asthma & ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

CRSwNP affects approximately 320 million people worldwide. The condition causes benign polyp growths in the nasal cavity and symptoms including congestion and reduced sense of smell. Current therapies ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE ® (tezepelumab-ekko) for the ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...

TUESDAY, Oct. 28, 2025 (HealthDay News) -- The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...